These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 26457764)
1. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764 [TBL] [Abstract][Full Text] [Related]
2. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761 [TBL] [Abstract][Full Text] [Related]
4. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704 [TBL] [Abstract][Full Text] [Related]
5. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Pacenta HL; Macy ME Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456 [TBL] [Abstract][Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
7. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803 [TBL] [Abstract][Full Text] [Related]
8. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC; Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015 [TBL] [Abstract][Full Text] [Related]
9. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357 [No Abstract] [Full Text] [Related]
10. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Frampton JE Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816 [TBL] [Abstract][Full Text] [Related]